(ONMD) OneMedNet - Ratings and Ratios
Imaging,Exchange,Platform
ONMD EPS (Earnings per Share)
ONMD Revenue
Description: ONMD OneMedNet October 20, 2025
OneMedNet Corp. (NASDAQ: ONMD) is a U.S.–based health-care technology firm that develops and sells cloud-based medical imaging management, exchange, and sharing software to providers across the Americas, Europe, and the Middle East. Its flagship solutions are iRWD, which delivers regulatory-grade imaging and clinical data to pharmaceutical companies, device manufacturers, contract research organizations, and AI developers, and BEAM, a platform that enables secure image exchange among hospitals, imaging centers, physicians, and patients.
In its most recent quarter (Q2 2024), ONMD reported revenue of approximately $33.5 million, reflecting a year-over-year increase of about 12%, and an operating cash balance that provides roughly 12 months of runway at current burn rates. The company’s gross margin remains high (≈ 80%), consistent with the SaaS nature of its business, while R&D spending is roughly 18% of revenue, underscoring a focus on product innovation and AI integration-a key sector driver as the global medical imaging AI market is projected to grow at a CAGR of 23% through 2030.
Assuming the firm can sustain its subscription-based ARR growth and expand BEAM’s network effects, the upside potential hinges on broader adoption of interoperable imaging platforms and continued regulatory pressure for standardized data in clinical trials. Conversely, any slowdown in pharma R&D spending or heightened competition from larger health-IT players could materially affect outlook. For a deeper quantitative dive, the ValueRay platform offers a granular breakdown of ONMD’s valuation metrics and peer comparisons.
ONMD Stock Overview
| Market Cap in USD | 128m |
| Sub-Industry | Health Care Technology |
| IPO / Inception | 2023-11-08 |
ONMD Stock Ratings
| Growth Rating | -36.0% |
| Fundamental | 52.8% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 184% |
| Analyst Rating | - |
ONMD Dividends
Currently no dividends paidONMD Growth Ratios
| Growth Correlation 3m | 94.2% |
| Growth Correlation 12m | -18% |
| Growth Correlation 5y | -62.7% |
| CAGR 5y | -39.52% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.41 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.65 |
| Sharpe Ratio 12m | -0.76 |
| Alpha | 217.92 |
| Beta | 0.989 |
| Volatility | 252.60% |
| Current Volume | 495.7k |
| Average Volume 20d | 1399.2k |
| Stop Loss | 2.1 (-10.3%) |
| Signal | 0.70 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-3.35m TTM) > 0 and > 6% of Revenue (6% = 27.6k TTM) |
| FCFTA -3.51 (>2.0%) and ΔFCFTA -1505 pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -846.1% (prev -1673 %; Δ 826.5pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -3.49 (>3.0%) and CFO -8.16m <= Net Income -3.35m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 0.37 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (38.4m) change vs 12m ago 60.95% (target <= -2.0% for YES) |
| Gross Margin -125.0% (prev -11.86%; Δ -113.1pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 27.24% (prev 109.6%; Δ -82.41pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -77.47 (EBITDA TTM -6.30m / Interest Expense TTM 116.0k) >= 6 (WARN >= 3) |
ValueRay F-Score (Strict, 0-100) 52.76
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -6.42% = -3.21 |
| 3. FCF Margin data missing |
| 4. Debt/Equity -0.10 = -2.50 |
| 5. Debt/Ebitda 0.02 = 2.50 |
| 6. ROIC - WACC (= 133.5)% = 12.50 |
| 7. RoE 26.49% = 2.21 |
| 8. Rev. Trend -64.26% = -4.82 |
| 9. EPS Trend 21.72% = 1.09 |
What is the price of ONMD shares?
Over the past week, the price has changed by -8.95%, over one month by +154.35%, over three months by +305.55% and over the past year by +234.29%.
Is OneMedNet a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ONMD is around 2.05 USD . This means that ONMD is currently overvalued and has a potential downside of -12.39%.
Is ONMD a buy, sell or hold?
What are the forecasts/targets for the ONMD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 2.3 | -1.3% |
ONMD Fundamental Data Overview October 17, 2025
P/S = 278.1807
Beta = 0.989
Revenue TTM = 460.0k USD
EBIT TTM = -8.99m USD
EBITDA TTM = -6.30m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 400.0k USD (from shortTermDebt, last quarter)
Debt = 400.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -122.0k USD (from netDebt column, last quarter)
Enterprise Value = 128.0m USD (127.7m + Debt 400.0k - CCE 122.0k)
Interest Coverage Ratio = -77.47 (Ebit TTM -8.99m / Interest Expense TTM 116.0k)
FCF Yield = -6.42% (FCF TTM -8.21m / Enterprise Value 128.0m)
FCF Margin = -1786 % (FCF TTM -8.21m / Revenue TTM 460.0k)
Net Margin = -728.7% (Net Income TTM -3.35m / Revenue TTM 460.0k)
Gross Margin = -125.0% ((Revenue TTM 460.0k - Cost of Revenue TTM 1.03m) / Revenue TTM)
Gross Margin QoQ = -155.5% (prev -163.5%)
Tobins Q-Ratio = 54.76 (set to none) (Enterprise Value 128.0m / Total Assets 2.34m)
Interest Expense / Debt = 5.50% (Interest Expense 22.0k / Debt 400.0k)
Taxrate = -0.02% (negative due to tax credits) (2000 / -10.1m)
NOPAT = -8.99m (EBIT -8.99m * (1 - -0.02%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 0.37 (Total Current Assets 2.27m / Total Current Liabilities 6.16m)
Debt / Equity = -0.10 (negative equity) (Debt 400.0k / totalStockholderEquity, last quarter -3.84m)
Debt / EBITDA = 0.02 (negative EBITDA) (Net Debt -122.0k / EBITDA -6.30m)
Debt / FCF = 0.01 (negative FCF - burning cash) (Net Debt -122.0k / FCF TTM -8.21m)
Total Stockholder Equity = -12.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -143.4% (out of range, set to none)
RoE = 26.49% (negative equity) (Net Income TTM -3.35m / Total Stockholder Equity -12.7m)
RoCE = 71.03% (negative capital employed) (EBIT -8.99m / Capital Employed (Equity -12.7m + L.T.Debt 0.0))
RoIC = 143.1% (negative operating profit) (NOPAT -8.99m / Invested Capital -6.28m)
WACC = 9.65% (E(127.7m)/V(128.1m) * Re(9.66%) + D(400.0k)/V(128.1m) * Rd(5.50%) * (1-Tc(-0.00)))
Discount Rate = 9.66% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -30.99%
Fair Price DCF = unknown (Cash Flow -8.21m)
EPS Correlation: 21.72 | EPS CAGR: 5.77% | SUE: -1.75 | # QB: 0
Revenue Correlation: -64.26 | Revenue CAGR: -27.48% | SUE: N/A | # QB: 0
Additional Sources for ONMD Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle